Compare AbCellera Biologics Inc (ABCL) vs ASML Holding NV (ASML) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs ASML Holding NV — how do they compare? AbCellera Biologics Inc trades at $10.09 (market cap $2.99B), while ASML Holding NV trades at $1,812.46 (market cap $689.17B). The key difference: ASML Holding NV is far larger — about 230.5× AbCellera Biologics Inc's market cap, and ASML Holding NV pays a 0.5% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ASML | |
|---|---|---|
Market Cap | $2.99B | $689.17B |
Sector | Health | Technology |
52-Week High | $9.76 | $1.99K |
52-Week Low | $2.78 | $725.85 |
Enterprise Value | $2.58B | $682.70B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
ASML trades at $1,733.48, down 0.43% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a 29.41% net income margin and robust revenue growth to $32.67B in 2025. Recent earnings beats in Q1 and Q2 2026, coupled with a consensus price target of $2,390, highlight positive momentum, though high valuation ratios like a P/E of 61.28 pose risks.
Outlook remains favorable due to AI-driven semiconductor demand, but investors face risks from geopolitical tensions with China and stretched valuations. Analyst consensus is strongly bullish with 57% buy ratings, supporting potential upside, though monitoring competitive threats and earnings consistency is crucial for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →
